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ABSTRACT 
Introduction: Esophageal perforation (EP) is a rare, often life-threatening condition, and its 
management is still challenging. The Pittsburgh group has suggested a perforation severity 
score (PSS) for better decision-making in the management of EP. The aim of this study was to 
propose a decision-making algorithm based in our experience of a quarter of century and to 
analyze the usefulness of the PSS in an independent study population.  
Material and Methods: Analysis of a prospective database with cases of EP (n=71) treated in 
an Upper GI Surgery Unit, between January 1991 and October 2014.  
Results: The majority of perforations were traumatic (60.6%) and thoracic (62.0%), and 22.5% 
were treated non-operatively. Morbidity and mortality were 40.8% and 15.5%. PSS was 
significantly higher in patients with fatal outcome (7.36 vs. 3.93;p=0.009), morbidity (6.55 vs. 
3.02;p<0.001) and operative cases (5.13 vs. 2.19;p<0.001). PSS presented an OR of 2.87 
(95%CI:1.06-7.75;p=0.037) for mortality, 5.10 (95%CI:2.19-11.91;p<0.001) for morbidity and 
4.70 (95%CI:1.78-12.35;p=0.002) for operative treatment. Most significant outcome predictors 
were PSS, clinical stability, non-contained leak, prior esophageal pathology, etiology and 
location of perforation. 
Conclusions: Based on these results, we propose a decision-making algorithm to best assist in 
the choice of EP treatment. The PSS reliably correlates with the seriousness of EP and is a 
useful tool to identify appropriate candidates for non-operative management. 
 
KEY WORDS: Esophageal perforation, Severity score, Decision-making algorithm, Outcomes, 
Non-operative management  
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INTRODUCTION 
Esophageal perforation (EP) is an uncommon condition of increasing incidence. This is mainly 
due to iatrogenic perforations, which have been reported as its leading cause, at least, since 
1970 [3, 4], despite the shift from rigid to flexible endoscopy [1-3]. The rising applicability and 
advantages of endoscopic procedures enhanced this tendency [5]. EP is associated to high 
mortality (10-40%) [6, 7] that, despite diagnosis, support and treatment developments, has 
shown few or no improvements for almost 50 years [4]. It is important to notice that these 
values are highly variable due to the limited number and high heterogeneity regarding 
patients, and lack of universally consistent approach. EP shows a great clinical heterogeneity 
due to its variability concerning location, cause, extent of lesion and the fact that it can mimic 
more common pathologies, such as: aortic dissection, myocardial infarction, acute 
pancreatitis, perforated ulcer, pneumothorax or pulmonary disease [7]. Hereupon, EP may 
present itself as a challenging diagnosis, explaining the extended time between presentation 
and diagnosis (more than 24 hours in 60% of the cases [8]). This delay, along with 
mediastinitis, sepsis and the initial diagnosis being incorrect in 50% of the cases, [7, 8], may 
partially explain the great morbidity and mortality of EP. [6, 7, 9-12] The approach and 
management of EP, depends greatly on medical experience and subjectivity, ranging from 
conservative treatment to radical esophagectomy. In 2009, Ghulam Abbas, MD et al.[9]  
proposed a “perforation score” to evaluate the ability some clinical factors could have in the 
decision-making process in order to generate an optimal therapeutic approach and better 
patient outcomes. They concluded that injury severity, degree of mediastinal and pleural 
contamination should greatly head approach to EP. They also concluded that non-operative 
management might be successfully implemented in selected patients with a low morbidity and 
mortality if favorable radiographic and clinical characteristics are present. In the current study, 
we evaluate the presentation, treatment and outcome of all cases of EP treated in a tertiary 
hospital during 24 years. We have applied the perforation severity score (PSS), evaluated its 
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feasibility and capability to guide clinical diagnosis and management in an independent study 
population. A decision-making algorithm is also proposed based in the analysis of our series 
and the lessons taken from our experience. 
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MATERIALS AND METHODS 
A prospective database with EP cases (n=71) treated in the Upper GI Surgery Unit of Centro 
Hospitalar São João (Porto, Portugal), between January 1991 and October 2014, was 
retrospectively reviewed. Institutional review board approval was obtained for this study (CES 
04-13). The following clinical and pathological parameters were evaluated: gender, age, 
etiology (spontaneous, iatrogenic or traumatic), type of traumatic lesion (fishbone, chicken 
bone, teeth prosthesis, aliment impaction, trauma or other), prior esophageal pathology 
(stricture, cancer, diverticulum or other), location (cervical, thoracic or abdominal), time to 
diagnosis (hours), type of management (operative or non-operative, including endoscopic 
treatment), type of surgery (primary repair, repair over drain, exclusion, esophagectomy, 
drainage only or other), minimally invasive approach, endoscopic stent insertion, need of 
surgery after non-operative management, morbidity, type of complications (empyema, 
mediastinitis, pneumonia, sepsis, leakage of the repair, stricture after repair or other), 
mortality, length of stay (LOS) [days] and follow-up. When the patient presented with more 
than one complication, the most severe (life-threatening) complication was accounted. In 
order to evaluate the PSS (range 0-18), ten clinical variables were obtained for each patient 
(Table 1). Variables were defined as suggested by Abbas et al [9]. The performance of PSS was 
assessed according to its capability to predict mortality, morbidity and type of management 
using the cut-off that presented better sensibility and specificity. In order to create a decision 
algorithm, patients were divided in 3 groups, as suggested by the Pittsburgh group, according 
to percentiles 25 and 75 of PSS: ≤2; 3-5; ≥6. Univariate and multivariate analysis were 
performed to correlate variables and outcome with PSS groups and assess the variables that 
could better guide decision. 
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Statistical analysis 
The statistical analysis was performed using IBM SPSS Statistics for Macintosh, Version 21.0. 
(Armonk, NY, USA: IBM Corp). Analyzing categorical variables, Pearson’s chi-square test or 
Fisher’s exact test were used when appropriate. Normal distribution was assessed using 
normality plots (visual assessment of histograms with the normal distribution curve and 
normal Q-Q plots) and tests (Kolmogorov-Smirnov and Shapiro-Wilk tests). Continuous 
variables were analyzed using t-Student test or non-parametric tests (Mann–Whitney U and 
Kruskal-Wallis tests) whenever appropriate. Receiver operating characteristic (ROC) curves 
were used to assess the performance of PSS in appropriate situations. Multivariate analysis 
used logistic regression to compare variables that had shown differences (p-value <0.2) related 
to mortality, morbidity or type of treatment in univariate analysis. All 3 analyses using forward 
stepwise method were performed twice: the first one considered PSS groups and not the 
variables that compose PSS, the second one considered the variables that compose PSS, but 
not PSS groups. The p-value considered statistically significant was <0.05. All p values given are 
results of 2-sided tests. 
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RESULTS 
The study comprises a total of 71 adult (≥18 year-old) patients. The median age at 
presentation was 62 (19-89) years, with 83.1% being ≤75 year-old. Thirty-six (50.7%) patients 
were female. No association was found between gender and morbidity (p=0.734) or mortality 
(p=0.705). Fifty-nine (83.1%) patients had no prior pathology, 4.2% and 1.4% had been 
previously diagnosed with esophageal cancer or stricture, respectively. The median timing of 
diagnosis was 24 (1-336) hours and 50.7% were diagnosed in the first 24 hours. The median 
LOS was 26 (4-266) days. The most common etiology was traumatic (60.6%) followed by 
iatrogenic (21.1%) and spontaneous (Boerhaave) accounting for 18.3%. Fish and chicken bones 
caused 74.4% of all traumatic perforations (39.5% and 34.9%, respectively).  Most lesions were 
thoracic (62%). Operative treatment (77.5%) was more common than non-operative 
management. Primary repair was the most common option (52.7%) in operative treatment. 
The morbidity and mortality rates were 40.8% and 15.5%, respectively. In the non-operative 
group, out of 16 treated patients, none died and only one needed posterior operative 
treatment. Empyema (9.9%) and sepsis (9.9%) were the most common complications.  
Morbidity was significantly associated to etiology (p=0.003), type of management (p=0.001) 
and PSS (p<0.001) [presence at presentation of tachycardia (p=0.001), pleural effusion 
(p<0.001), non-contained leak (p<0.001), respiratory compromise (p<0.001) and hypotension 
(p=0.012)]. No statistic significant association was found between morbidity and location of 
perforation (p=0.058). Mortality was significantly associated to age (p=0.007), etiology 
(p=0.02), esophageal pathology (p=0.002), location (p=0.004) and PSS (p=0.009) [age >75 years 
(p=0.016), presence at presentation of tachycardia (p=0.002), hypotension (p=0.006) and 
cancer (p=0.035)]. Type of management did not significantly affect mortality (p=0.052). The 
timing of diagnosis didn't significantly influence morbidity or mortality (p=0.699 and 0.389 
respectively). Type of management was significantly associated to periods (p=0.03), LOS 
(p<0.001) and PSS (p<0.001) [presence at presentation of tachycardia (p=0.020), pleural 
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effusions (p=0.016), non-contained leak (p=0.004) and respiratory compromise (p=0.003)]. A 
more detailed description of the demographics and univariate analysis according to morbidity, 
mortality and type of management are depicted in Table 2. Cases were divided in 8-year 
periods (1991-1998; 1999-2006; 2007-2014) and no association was found (Table 3) between 
the periods and mortality (p=0.617), morbidity (p=0.381), LOS (p=0.054) or PSS (p=0.394). 
Association was significant between 8-year periods and type of treatment (p=0.03). 
The median PSS was 4 (range 0-14). The 25 and 75 percentiles were 2 and 6, respectively 
(Figure 1).  PSS was significantly higher in patients with fatal outcome (7.36 ± 4.13 vs. 3.93 ± 
2.69; p=0.009) and in morbidity cases (6.55 ± 3.52 vs. 3.02 ± 1.88; p<0.001). Moreover PSS was 
significantly higher in operative cases (5.13 ± 3.22 vs. 2.19 ± 1.64; p<0.001). Dividing all 
patients according to PSS (cut-off in the middle possible value: <9 and ≥9), the first group 
showed over 10 higher odds of survival (OR: 10.86; 95% CI: 2.00-58.86; p=0.006). The ROC 
curves for PSS showed a good prediction of morbidity (AUC=0.801; p<0.001), mortality 
(AUC=0.745; p=0.010) and type of management (AUC=0.795; p<0.001) (Figures 2, 3 and 4). 
Regarding mortality and morbidity, PSS cut-off that has shown the best likehood ratios (1,488 
and 1,753, respectively) was the value 4. About mortality, PSS ≥4 showed sensibility and 
specificity of 81.8% and 45.0%, respectively and diagnostic OR of 3.682. Concerning morbidity, 
PSS ≥4 showed sensibility and specificity of 79.3% and 54.8%, respectively, and a diagnostic OR 
of 4.640. As for the ROC curve of PSS and type of management, the best cut-off was 4, with 
likehood ratio of 2.426. PSS <4 was related with non-operative treatment with a sensibility of 
75% and specificity of 69.1%, and a diagnostic OR of 6.706.  
As suggested by the Pittsburgh group [9], patients were divided in three groups: PSS ≤2; PSS 3-
5; PSS ≥6 (cut-offs based in percentiles 25 and 75). Groups were named 1 (low risk), 2 
(moderate risk) and 3 (high risk), respectively. Twenty patients were allocated to group 1 
(28.2%), and the same for group 3. In group 2 were the remaining 31 patients (43.6%). Groups 
were significantly associated to morbidity, type of management and LOS (p<0.001, p=0.003 
9 
 
and p<0.001, respectively), but not to mortality (p=0.080) (Table 4). Univariate analysis was 
performed to compare those groups regarding mortality and morbidity. Results are resumed in 
Table 5. The analysis of the PSS groups presented an OR of 2.87 (95% CI: 1.06-7.75; p=0.037) 
for mortality, OR of 5.10 (95% CI: 2.19-11.91; p<0.001) for morbidity and OR of 4.70 (95% CI: 
1.78-12.35; p=0.002) for type of management, with significant higher mortality, morbidity and 
operative treatment rate in group 3. 
Multivariate analyses were performed to determine the variables that had most influence on 
mortality, morbidity and type of management. As explained above, 2 models with different 
variables included were analyzed for each outcome. The 2 models for morbidity included: 
etiology, location, PSS and the following PSS parameters: age >75 years, tachycardia, pleural 
effusion, non-contained leak, respiratory compromise and hypotension. The 2 models for 
mortality included: etiology, prior esophageal pathology, location, PSS and the following PSS 
parameters: age >75 years, tachycardia, pleural effusion, non-contained leak, hypotension and 
cancer. The 2 models for type of treatment included: PSS groups and the following PSS 
parameters: tachycardia, pleural effusion, non-contained leak, respiratory compromise and 
hypotension. The variables that showed to be significant outcome predictors are detailed in 
Table 6.  
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DISCUSSION 
Demographics 
The current data shows that EP remains a challenging diagnosis with highly variable 
presentation. It affects all ages, genders and, regardless medicine development, morbidity and 
mortality rates show no significant improvement. It is important, although, to notice that some 
substantial differences have been brought to light in this population. Regarding etiology, it is of 
great importance the fact that traumatic cause is, by far, the most common (60.6%) and  
iatrogenic perforations,  which have been described as leading cause at least for the last 50 
years [4, 6, 7, 12-15], account for only 21.1%. No obvious cause or bias yields up, once all 
patients treated in a tertiary hospital are included (apart from pediatric population). A possible 
cause could be the Portuguese alimentary habits, since 74.4% of traumatic perforations were 
caused by chicken or fish bones, especially codfish bones. Further conclusions would be highly 
speculative since, although fish and chicken bones are generally reported among the most 
common causes [5, 7], the specific cause of traumatic perforations is not specified in most 
studies.    
 
Management 
Interestingly, despite the differences in etiology distribution of this series, the  outcomes 
(mortality and morbidity rates, operative/non-operative treatment ratio, LOS) were similar to 
those described in the literature [3, 6, 7, 11-14, 16, 17]. Time to diagnosis, that is widely 
referred as a important outcome predictor[7, 12, 18-23], being associated, when over 24 
hours, with up to 5 fold increase in mortality[3, 7, 23], was not significantly associated with 
increased mortality or morbidity (p=0.389 and p=0.699, respectively) in the present study. 
Such difference shows no evident cause, given that the number of patients with time to 
diagnosis ≤24h (50.7%) is comparable to most literature reports [7, 8, 13, 14].  We hypothesize 
that this may be due to the major difference in the etiology of EP referred above.  
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Decision between operative or non-operative treatment is an important choice for each 
patient, and it’s, many times, empirically based on surgeon’s experience and knowledge.   Non-
operative management, which includes, in recent years, an increasing use endoscopic 
treatment [24-27], is generally associated with better prognosis, depending on being rightly 
adjudicated to select patients [7, 15, 17, 25, 28]. As reported in most recent series, about one 
in every four patients might be treated non-operatively [6, 7]. This is similar to what reports 
our study (22.5%). As expected, according to the relatively recent interest and knowledge 
regarding non-operative management, this approach has shown to be an increasing option in 
our hospital, accounting for 9.5% of EP patients treated in 1991-1998, 16% in 1999-2006 and 
40% in 2007-2014. However, this increase was not accompanied by a significant difference 
regarding LOS neither mortality and morbidity rates (Table 3). It should be pointed out that the 
use of stents in patients with cancer as a palliative treatment may be a cause of bias, since 
patients with worse prognosis a priori are included in the non-operative group. In our study, 
no patient with cancer was treated non-operatively. In our series, one patient was treated with 
stent (had no diagnosis of cancer) and non-operative management was associated with better 
outcome regarding morbidity (p=0,001), but not regarding mortality (p=0.052), although no 
patients treated non-operatively (n=16) died. Several factors have been suggested as guidance 
to decide between operative and non-operative treatment [7, 29]. Among them is the PSS [9], 
that we apply and evaluate here. 
 
Perforation Severity Score 
PSS has shown to be a useful tool guiding decision on EP management [9, 13]. In our series, 
PSS was significantly higher in patients with a fatal outcome  (7.36 ± 4.13 vs. 3.93 ± 2.69; 
p=0.009) and in morbidity cases (6.55 ± 3.52 vs. 3.02 ± 1.88; p<0.001). Accordingly, PSS was 
significantly higher in operative cases (5.13 ± 3.22 vs. 2.19 ± 1.64; p<0.001). We also found that 
the ones with PSS <9 showed over 10 higher odds of survival (OR: 10.86; 95% CI: 2.00-58.86; 
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p=0.006). All this data is in favor of PSS utility even in a particular population as ours. In order 
to evaluate PSS strength to envisage outcome, ROC curves analyzing PSS as predictor of 
mortality, morbidity and type of management were elaborated. The ROC curves showed a 
good prediction of all 3 variables evaluated according to their AUC. The PSS cut-off of 4 for 
morbidity, mortality and type of management has shown good accuracy regarding sensitivity 
and specificity: 81.8% and 45.0%, for mortality; 79.3% and 54.8% for morbidity; 75% and 69.1% 
for type of management. Our data show that PSS highly correlates with seriousness of EP. A 
comparison of PSS values between non-operative patients and non-operative patients that had 
conversion to operative treatment would be interesting to see if those patients, according to 
PSS, should have been submitted to operative treatment in the first place. That analysis is not 
possible in the current series since only one patient needed the conversion from non-operative 
to operative management.  
 
Decision algorithm 
Decision algorithms in EP are always limited by the great heterogeneity of cause, presentation 
and patient background. However, a validated algorithm would be of great interest guiding 
management in EP, given the lack of universal consensus in treatment options and the rarity of 
the condition, both contributing to a lack of solid evidence-based medicine.  We propose a 
decision-making algorithm (Figure 5), requiring further validation, based on PSS and clinical 
signs, which have shown consistently good prognosis association in patient treatment [9, 13]. 
The correlation between PSS and EP management is in favor of its usefulness in directing 
patient treatment. Converting PSS to a dichotomous variable (using 4 as cut-off, as seen 
above) shows good correlation with outcome, but the amount of false negative cases suggests 
it may not be enough to guide management per se. The Pittsburgh group suggested patients to 
be divided in three groups [9]. Based in the 25 and 75 percentiles of our PSS distribution, 3 
groups were formed (low, moderate and high risk). Distribution of patients among groups was 
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as follows: 28.2% in group 1, 43.6% in group 2 and 28.2% in group 3. Mortality and morbidity 
increased, and percentage of non-operative treatment decreased, from group 1 to group 3. 
Those differences were statistically significant for morbidity and type of treatment, but not for 
mortality. However, the analysis of the PSS groups presented an OR of 2.87 (95% CI: 1.06-7.75; 
p=0.037) for mortality, OR of 5.10 (95% CI: 2.19-11.91; p<0.001) for morbidity and OR of 4.70 
(95% CI: 1.78-12.35; p=0.002) for operative management, with significant higher mortality, 
morbidity and operative treatment rate in group 3. Those statistically significant differences 
were not as striking or always significantly different when comparing groups individually (Table 
5). Those main differences are mostly seen when comparing groups 1 or 3 with group 2, 
although  the mortality rate difference between groups 3 and 1 was not statistically significant 
(p=0.065) (what might be seen as a considerable trend toward significance). Those data 
strongly suggest PSS utility in guiding management of EP, although group 2 patients should go 
under a further decision chain. In order to do so, multivariate analyses were performed in 
order to assess the variables that presented as stronger prognosis predictors regarding 
mortality, morbidity and type of management (Table 6). Therefore, those variables (non-
contained leak, clinical stability - respiratory compromise and tachycardia, location of EP and 
previous esophageal pathology) would be the better option to guide patients through the 
algorithm in groups 2. The subsequent steps of the algorithm were based on multivariate 
analyses and clinical experience, and turned out to be substantially similar to most algorithms 
suggested by various studies [1, 3, 5-7, 11, 13-15, 30].  
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CONCLUSION 
Based on these results, we propose a decision-making algorithm to best assist in the choice of 
EP treatment. The PSS reliably correlates with the seriousness of EP and is a useful tool to 
identify appropriate candidates for non-operative management. Although the possible 
catastrophic prognosis, the opposite is also true. The avoidance of unnecessary interventions 
with consequent morbidity is a must, but should not compromise aggressive treatment when 
needed.      
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Table 1. Perforation severity score  
Variable Value 
Age >75 years 1 
Tachycardia (>100 bpm) 1 
Leukocytosis (> 10,000 WBC/ml) 1 
Pleural effusions (on chest X-ray, CT, or barium swallow test) 1 
Fever (>38.5°C) 2 
Non-contained leak (on barium swallow test or CT) 2 
Respiratory compromise (respiratory rate >30, increasing oxygen requirement, or 
need for mechanical ventilation) 
2 
Time to diagnosis >24 hours 2 
Presence of hypotension at presentation 3 
Presence of cancer 3 
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Table 2. Demographics and univariate analyses according to the presence of morbidity, 
mortality and non-operative treatment 
 
All patients,  
n (%)  
Morbidity,  
n (%)  
Mortality, 
n (%)  
Non-operative 
treatment,  
n (%)  
Age  NS (p=0.06)* p=0.007* NS (p=0.405)* 
Mean ± SD 61.06 ± 14.86    
Presence vs.  
absence 
 65.03 ± 11.84 vs. 
58.31 ± 16.19 
72.00 ± 8.15 vs. 
59.05 ± 14.97 
58.31 ± 13.87 vs. 
61.85 ± 15.16 
Gender  NS (p=0.734) NS (p=0.705) NS (p=0.230) 
Female 36 (50.7) 14 (38.9) 5 (13,9) 6 (16.7) 
Male 35 (49.3) 15 (42.9) 6 (17.1) 10 (28.6) 
Etiology of perforation  p=0.003 p=0.02 NS (p=0.3) 
Spontaneous  13 (18.3) 10 (76.9) 5 (38.5) 1 (7.7) 
Iatrogenic 15 (21.1) 2 (13.3) 3 (20.0) 3 (20.0) 
Traumatic 43 (60.6) 17 (39.5) 3 (7.0) 12 (27.9) 
Esophageal pathology  NS (p=0.306) p=0.002 NS (p=0.241) 
No prior pathology 59 (83.1) 25 (42.4) 6 (10.2) 16 (27.1) 
Stricture 1 (1.4) 1 (100) 1 (100) 0 (0.0) 
Cancer 3 (4.2) 0 (0.0) 0 (0.0) 0 (0.0) 
Others 8 (11.3) 3 (37.5) 4 (50.0) 0 (0.0) 
Location of perforation  NS (p=0.058) p=0.004 NS (p=0,759) 
Cervical 17 (23.9) 3 (17.6) 1 (5.9) 3 (17.6)  
Thoracic 44 (62.0) 20 (45.5) 5 (11.4) 10 (22.7) 
Abdominal 10 (14.1) 6 (60.0)  5 (50.0) 3 (30.0) 
Type of management  p=0.001 p=0.052 - 
Operative 55 (77.5) 28 (50.9) 11 (20.0) - 
Non-operative 16 (22.5) 1 (6.3) 0 (0.0) - 
Type of operative management  p=0.342 p=0.437 - 
Primary repair 29 (52.7) 16 (55.2) 8 (27.6) - 
Exclusion 21 (38.2) 11 (52.4) 3 (14.3) - 
Esophagectomy 2 (3.6) 1 (50.0) 0 (0.0) - 
Drainage only 3 (5.5) 0 (0.0) 0 (0.0) - 
LOS (days)  p<0.001** NS (p=0.830)** p<0.001** 
Median [range] 26 [4-266]    
Mean ± SD, Presence vs. 
absence 
  63.97 ± 54.39 vs. 
25.86 ± 26.84 
36.18 ± 26.3 vs. 
42.38 ± 46.94 
11.94 ± 6.27 vs. 
50 ± 26.89 
PSS  p<0.001** p=0.009** p<0.001** 
Median [range] 4 [0-14]    
Mean ± SD, Presence vs. 
absence 
 6.55 ± 3.52 vs. 
3.02 ± 1.88 
7.36 ± 4.13 vs. 
3.93 ± 2.69 
2.19 ± 1.64 vs. 
5.13 ± 3.22 
Age >75 years  NS (p=0.176) p=0.006 NS (p=0.196) 
Yes 12 (16.9) 7 (58.3) 5 (41.7) 1 (8.3) 
No 59 (83.1) 22 (37.3) 6 (10.2) 15 (25.4) 
Tachycardia   p=0.001 p=0.001 p=0.02 
Yes 21 (29.6) 15 (71.4) 8 (38,1) 1 (4.8) 
No 50 (70.4) 14 (28.0) 3 (6.0) 15 (30.0) 
Leukocytosis   NS (p=0.678) NS (p=0.735) NS (p=0.757) 
Yes 29 (40.8) 11 (37.9) 5 (17.2) 6 (20.7) 
No 
 
42 (59.2) 
18 (42.9) 6 (14.3) 
10 (23.8) 
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Pleural effusions   p<0.001 NS (p=0.178) p=0.016 
Yes 32 (45.1) 22 (68.8) 7 (21.9) 3 (9.4) 
No 39 (54.9) 7 (17.9) 4 (10.3) 13 (33.3) 
Fever  NS (p=0.319) NS (p=0.789) NS (p=0.682) 
Yes 11 (15.5) 3 (27.3) 2 (18.2) 3 (27.3) 
No 60 (84.5) 26 (43.3) 9 (15.0) 13 (21.7) 
Non-contained leak   p<0.001 NS (p=0.166) p=0.004 
Yes 20 (28.2) 17 (85.0) 5 (25.0) 0 (0.0) 
No 51 (71.8) 12 (23.5) 6 (11.8) 16 (31.4) 
Respiratory compromise   p<0.001 NS (p=0.209) p=0.003 
Yes 21 (29.6) 16 (76.2) 5 (23.8) 0 (0.0) 
No 50 (70.4) 13 (26.0) 6 (12.0) 16 (32.0) 
Time to diagnosis >24 hours  NS (p=0.591) NS (p=0.405) NS (p=0.447) 
Yes 34 (47.9) 15 (44.1) 4 (11.8) 9 (26.5) 
No 37 (52.1) 14 (37.8) 7 (18.9) 7 (18.9) 
Hypotension at presentation  p=0.007 p=0.001 NS (p=0.066) 
Yes 10 (14.1) 8 (80.0) 5 (50.0) 0 (0.0) 
No 61 (85.9) 21 (34.4) 6 (9.8) 16 (26.2) 
Presence of cancer  NS (p=0.909) p=0.035 NS (p=0.133) 
Yes 7 (9.9) 3 (42.9) 3 (42.9) 0 (0.0) 
No 64 (90.1) 26 (40.6) 8 (12.5) 16 (25.0) 
SD, Standard deviation; PSS, Perforation severity score; NS, Non-significant  
* t-Student test 
** Mann-Whitney U test 
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Table 3. Outcomes univariate analysis according to 8-year periods  
 
First period 
 (1991-1998) 
Second period 
(1999-2006) 
Third period 
 (2007-2014) 
p-value 
n  21 25 25 - 
Morbidity, n (%) 9 (42.9) 11 (44.0) 9 (36.0) NS (0.827) 
Mortality, n (%) 2 (9.5) 4 (16.0) 5 (20.0) NS (0.617) 
Non-operative 
treatment, n (%) 
2 (9.5) 4 (16.0) 10 (40.0) 0.03 
LOS (days), 
mean ± SD 
50.19 ± 39.90 47.80 ± 57.00 27.68 ± 28.94 NS (0.054)* 
PSS, mean ± SD 4.95 ± 3.28 4.60 ± 2.92 3.92 ± 3.38 NS (0.394)* 
LOS, Length of stay; PSS, Perforation Severity Score; SD, Standard Deviation, NS, Non-
significant 
* Kruskal-Wallis test 
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Table 4. Outcomes univariate analysis according to perforation severity score 
groups  
 
Group 1 
(PSS ≤ 2) 
Group 2 
(PSS 3-5) 
Group 3 
(PSS ≥ 6) 
p-value 
n 20 31 20 - 
Morbidity, n (%) 3 (15.0) 10 (32.3) 16 (80.0) <0.001 
Mortality, n (%) 1 (5.0) 4 (12.9) 6 (30.0) NS (0.08) 
Non-operative 
treatment, n (%) 
9 (45.0) 7 (22.6) 0 (0.0) 0.003 
LOS (days), 
mean ± SD 
20.15 ± 20.44 39.71 ± 37.25 65.35 ± 59.43 <0.001* 
LOS, Length of stay; PSS, Perforation Severity Score; SD, Standard Deviation, NS, Non-
significant 
* Kruskal-Wallis test 
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Table 5. Univariate analysis of perforations severity score groups according to 
mortality and morbidity  
PSS 
Groups 
Mortality Morbidity 
OR 95% CI p-value OR 95% CI p-value 
3 vs. 2 2.890 0.699-11.972 0.143 8.400 2.223-31.744 0.002 
3 vs. 1 8.143 0.878-75.749 0.065 22.667 4.374-117.468 <0.001 
2 vs. 1 2.817 0.291-27.027 0.371 2.695 0.639-11.364 0.177 
CI, Confidence interval; OR, Odds ratio; PSS, Perforation severity score 
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Table 6. Multivariate Logistic Regression Analyses (Forward Stepwise 
Method): Significant outcome predictors for each model 
 
Model accuracy 
rate, % 
OR (95%CI) p-value 
Morbidity    
Model 1 (PSS groups) 
1
 76.1   
PSS Groups  5.10 (2.19-11.90) <0.001 
Model 2 (PSS variables) 
2
 83.1   
Non-contained leak  12.59 (2.94-53.91) 0.001 
Respiratory compromise   5.47 (1.43-20.94) 0.013 
Mortality    
Model 1 (PSS groups) 
3
 90.1   
Etiology of perforation  2.42 (1.03-5.68) 0.043 
Location of perforation  3.89 (1.09-13.89) 0.036 
Model 2 (PSS variables) 
4
 87.3   
Previous esophageal 
pathology 
 1.70 (1.03-2.81) 0.040 
Location of perforation  4.90 (1.16-20.83) 0.030 
Tachycardia  9.30 (1.73-50.03) 0.009 
Type of management    
Model 1 (PSS groups) 
5
 77.5   
PSS Groups  4.69 (1.78-12.35) 0.002 
Model 2 (PSS variables) 
6
 -   
None  - - 
CI, Confidence interval; OR, Odds ratio; PSS, Perforation severity score 
Variables included in the models (based in univariate analyses p-value <0.2): 
1. Etiology, location and PSS 
2. Etiology, location, age, tachycardia, pleural effusion, non-contained leak, respiratory 
compromise and hypotension 
3. Etiology, location, previous esophageal pathology and PSS 
4. Etiology, location, previous esophageal pathology, age, tachycardia, pleural effusion, non-
contained leak, hypotension and cancer 
5. PSS 
6. Tachycardia, pleural effusion, non-contained leak, respiratory compromise and hypotension 
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Figure 1. Perforation severity score distribution in study population  
 
Median PSS was 4 (0-14), percentiles 25 and 75 were 2 and 6, respectively 
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Figure 2. ROC curve for perforation severity score association with morbidity 
The ROC curve for PSS showed a good prediction of morbidity (AUC=0.801; p<0.001). PSS cut-
off value 4 has shown the best likehood ratio (1,753), sensibility of 79.3% and specificity of 
54.8%, and diagnostic odds ratio of 4.640. 
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Figure 3. ROC curve for perforation severity score association with mortality 
The ROC curve for PSS showed a good prediction of morbidity (AUC=0.801; p<0.001). PSS cut-
off value 4 has shown the best likehood ratio (1,488), sensibility of 81.8% and specificity of 
45.0%, and diagnostic odds ratio of 3.682. 
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Figure 4. ROC curve for perforation severity score association with non-operative treatment 
The ROC curve for PSS showed a good prediction of non-operative management (AUC=0.795; 
p<0.001). PSS cut-off value 4 has shown the best likehood ratio (2.426), sensibility of 75% and 
specificity of 69.1%, and diagnostic odds ratio of 6.706. 
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Figure 5. Proposed decision-making algorithm for EP management 
Based in univariate and multivariate analyses according to morbidity, mortality, type of 
management and PSS. Most significant outcome predictors were PSS categorized in low (≤2), 
moderate (3-5) and high risk (≥6) groups, clinical stability (respiratory compromise and 
tachycardia), non-contained leak, prior esophageal pathology, etiology and location of 
perforation. 
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